SLE疲劳与抗NMDAR自身抗体的诊断及致病作用
该研究分析426例SLE患者血清抗NR2抗体,发现其滴度与疲劳严重程度、SLEDAI 2000及抗dsDNA抗体相关,且不依赖神经精神性狼疮表现。抗NR2抗体存在于脑脊液、结合海马NMDAR并在体外下调神经元能量代谢;贝利尤单抗治疗至少6个月可影响疲劳严重程度和抗NR2抗体水平。
要点
- 抗NR2抗体滴度与SLE患者疲劳严重程度及疾病活动度相关。
- 抗NR2抗体可在脑脊液检出并结合海马NMDAR,体外下调神经元能量代谢。
- 贝利尤单抗治疗至少6个月可影响疲劳严重程度和抗NR2抗体水平。
核心结论
- SLE伴疲劳患者中抗NR2抗体存在有助于诊断,并可能为疲劳这一致残症状提供重要治疗靶点。
研究设计与样本
- 分析426例SLE患者血清抗NMDAR NR2亚单位抗体,并以疲劳量表评估疲劳严重程度。
- 在部分SLE患者中将海马体积与抗NR2抗体水平进行关联分析。
- 用抗NR2抗体阳性患者分离的IgG进行小鼠免疫组化实验和神经元细胞系功能实验。
- 在86例接受贝利尤单抗治疗的狼疮患者中研究治疗效应。
主要发现
- 抗NR2抗体滴度与疲劳严重程度、SLEDAI 2000及抗dsDNA抗体密切相关的,且不依赖神经精神性狼疮表现。
- 抗NR2抗体可在脑脊液中检出,并在海马区原位结合NMDAR。
- 体外实验中抗NR2抗体下调神经元细胞能量代谢,但未增强细胞毒性。
- 贝利尤单抗治疗至少6个月影响疲劳严重程度和抗NR2抗体水平。
临床怎么用
- 对SLE伴疲劳患者可检测抗NR2抗体作为辅助诊断工具。
- 抗NR2抗体可能成为SLE疲劳治疗管理的重要靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We explored the impact of circulating anti-N-methyl-D-aspartate receptor (NMDAR) antibodies on the severity of fatigue in patients with systemic lupus erythematosus (SLE). METHODS: Serum samples of 426 patients with SLE were analysed for the presence of antibodies to the NR2 subunit of the NMDAR. In parallel, the severity of fatigue was determined according to the Fatigue Scale for Motor and Cognitive functions questionnaire. In a subgroup of patients with SLE, the hippocampal volume was correlated with the levels of anti-NR2 antibodies. Isolated immunoglobulin G from patients with anti-NR2 antibodies were used for murine immunohistochemical experiments and functional assays on neuronal cell lines. Treatment effects were studied in 86 patients with lupus under belimumab therapy. RESULTS: We found a close correlation between the titre of anti-NR2 antibodies, the severity of fatigue, the clinical disease activity index (Systemic Lupus Erythematosus Disease Activity Index 2000) and anti-double stranded DNA antibodies-independently of the presence of neuropsychiatric lupus manifestations. Pathogenic effects could be demonstrated by (1) detection of anti-NR2 antibodies in the cerebrospinal fluid, (2) in situ binding of anti-NR2 antibodies to NMDAR of the hippocampus area and (3) distinct functional effects in vitro: downregulating the energy metabolism of neuronal cells without enhanced cytotoxicity. Treatment with belimumab for at least 6 months affected both the severity of fatigue and the levels of anti-NR2 antibodies. CONCLUSION: The presence of anti-NR2 antibodies in patients with SLE with fatigue is a helpful diagnostic tool and may offer a major approach in the therapeutic management of this important disabling symptom in patients with SLE.
引用
- Schwarting A, Möckel T, Lütgendorf F, et al. Fatigue in SLE: diagnostic and pathogenic impact of anti-N-methyl-D-aspartate receptor (NMDAR) autoantibodies. Ann Rheum Dis. 2019. PMID: 31186256. doi:10.1136/annrheumdis-2019-215098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。